Developing small activating RNA as new class of medicines.

- Evaluated investment opportunities, preparing five internal investment memoranda- Built financials models and drafted term sheets / letters of interest for equity and convertible loan investments of $30m – $60m in chemicals, pharmaceuticals, manufacturing and entertainment industries- Prepared detailed management Q&As following review of due diligence materials

- Lead and coordinated license agreement with major medical device company - Prepared financial forecasts and business plan - Lead investor meeting and presentation

Advised on a number of public and private takeovers including - RSA Insurance Group on its bid for $8bn of assets of Aviva - Kraft Foods on its $22bn hostile acquisition of Cadbury - Mastercard on its $0.5bn acquisition of Datacash - Lily Consortium on its bid for LCH.ClearnetWork streams included: - Complex financial modelling with operational, capital structure and M&A components - Valuation - Public deal process including key documentation - Competition analysis - M&A tactics